Britain and America have hammered out a landmark bilateral deal that will ensure zero tariffs on UK medicine products going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these crucial goods will remain at nothing for a timeframe of three years.
This deal is in response to recent threats to hike tariffs on patented drug imports, with figures floated as high as one hundred percent.
"This agreement with the United Kingdom reinforces the global environment for new treatments and brings much-needed equity to transatlantic drug exports," a release said.
Commercial Importance
Pharmaceuticals represent one of the the United Kingdom's most significant export categories to the America, which is clearly the primary market for major companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of the third quarter, the UK shipped drugs worth over eleven billion pounds to the US. This amount accounted for 17.4% of all goods exports in that span.
"This agreement safeguards work, stimulates capital expenditure and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The agreement includes several specific commitments from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to double total NHS spending on treatments from 0.3% of the national economy to 0.6% over the next decade.
- Refund Ceiling: The amount drug companies must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments were more than 20%.
Recent Tensions
This agreement takes place against a ongoing tension between the sector and the British authorities over medicine costs and approval rates.
These tensions were heightened by claims that American consumers were paying several times more for the same drugs than people in the Britain and the EU.
Recently, several significant drug company projects in the UK have been delayed or cancelled, while substantial expansions have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had declined as a share of its overall budget over the previous ten-year period.
